NCT01537159

MRI Assessment of Leukemia Response to Therapy

Quantitative DCE-MRI as a Predictor of Therapeutic Response in Acute Leukemia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 23 (actual)
• Sponsor: OHSU Knight Cancer Institute · Academic / Other
• Sex: All
• Age: 8 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate if a type of magnetic resonance imaging (MRI) scan of the bone marrow before the start of standard chemotherapy can predict complete remission of leukemia patients after the therapy. This type of MRI scan, called dynamic contrast-enhanced MRI (DCE-MRI), measures bone marrow blood flow. For those patients who do not achieve complete remission status after initial therapy and will be treated with additional therapy, the investigators are also interested in determining if the second MRI exam before the additional therapy can predict complete remission. If successfully tested, the MRI exam may be used in the future to help with early identification of patients who are unlikely to respond to standard chemotherapy. This will allow for a personalized therapeutic plan to be developed for these patients at an early stage and prevent them from being exposed to toxic and ineffective therapies.

Conditions

• Acute Myelogenous Leukemia

Interventions

Type	Name	Description
DEVICE	3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system	Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.

Timeline

• Start date: 2012-05-01
• Primary completion: 2018-12-31
• Completion: 2018-12-31
• First posted: 2012-02-23
• Last updated: 2019-07-30

Locations

1 site across 1 country: United States